Kornimate/medical-research-clean huggingface dataset:
using the energy gap to prevent weight regain

Conditions: Obesity

Summary: the major challenge in obesity treatment is not producing weight loss but in preventing that weight from being regained. there are many different methods to lose weight, but there are no recommendations for how you can best achieve long-term weight loss maintenance. despite the method used to reduce one's body weight, very few of these individuals are able to keep their weight off permanently. this project aims to identify how much activity is necessary to prevent weight regain after weight loss.


Eligibility criteria:
inclusion criteria: 1. all ethnic groups and both genders 2. age: lower age limit: 19 years; upper age limit: 45 years 3. body-mass index: lower bmi limit: 30 kg/m2; upper bmi limit: 40 kg/m2 and weight stable within +/- 5 pounds in the last 6 months, and currently at maximum non pregnant body weight (+/- 5%) 4. a negative treadmill stress test or subsequent follow up cardiac testing for cardiac ischemia. exclusion criteria: 1. history of cardiovascular disease, including coronary artery disease, congestive heart failure, \& unstable angina, or uncontrolled hypertension ( \> 140/90 mm hg) 2. currently smoking or stopped smoking in the last 12 months 3. medications affecting weight, energy intake, or energy expenditure in the last 6 months 4. use of oral steroids within the last 12 months 5. history of stroke or seizures, thyroid disease, type 1 or 2 diabetes, cushings syndrome, cerebrovascular, renal disease, hepatic disease, arrhythmias 6. cancer requiring treatment in the past 5 years, with the exception of skin cancers other than melanoma 7. infectious diseases: self-reported hiv positivity or active tuberculosis 8. weight loss or weight gain of \> 5% in past 6 months for any reason except post-partum weight loss 9. likely to move away in next 1.5 years 10. inability to adhere to the program such as inability to increase walking 11. currently pregnant, lactating or less than 6 months post-partum 12. major psychiatric disorder: exclusions related to medications -antipsychotic agents (these include, but are not limited to: haldol, loxitane, mellaril, navane, prolixin, stelazine, thorazine, and trilafon) 13. current depression by history or beck depression inventory (bdi) 14. currently being treated for psychological condition

Keywords: weight maintenance weight loss
intraoral appliance in the treatment of obstructive sleep apnea syndrome in obese

Conditions: Obstructive Sleep Apnea; Obesity

Summary: this study evaluates the effectiveness of intraoral appliance in the treatment of obstructive sleep apnea syndrome in class iii obese in comparison to an adjustable silicone appliance. both treatments will be test by all of the participants and they will make the polysomnography exam to have the outcomes.


Eligibility criteria:
inclusion criteria: * bmi ≥40 kg/m² and ≤ 49,9 kg/m² * female and male patients (both of gender patients) with ages between 20 to 65 years old * obstructive sleep apnea (osa) diagnosis by polysomnography exclusion criteria: * sedative drugs users * oxygen-dependent or decompensated lung disease * decompensated congestive heart failure * signs and symptoms of other sleeping disorders (narcolepsy, restless legs syndrome, insomnia) * craniofacial deformities carriers * previous osas diagnosis and treatment * active oncological diseases in the last ten years * patients with less than 8 teeth per arcade; * patients with advanced periodontitis;
polycystic ovary syndrome and education

Conditions: Quality of Life

Summary: aim: this research is being designed to determine the effect of polycystic ovary syndrome (pcos) education given to women on their quality of life. in this context, the aim of the project is; the aim is to determine the impact of the education given to women with pcos on the quality of life of the training given to women with the disease, such as psychosocial and emotional status, fertility, sexual function, obesity and menstrual irregularity, and hair growth. method: within the scope of this research, quantitative research method is used as the research method. in addition, it is planned as a randomized controlled quasi-experimental, which is one of the quantitative research methods. in calculating the sample size, type 1 error, research power and effect size parameters are determined before the research begins. studies generally need to have at least 80% power. in order to find a significant difference, it is calculated that there should be at least 30 students in each group at 80% power and 95% confidence level. considering the possible risks, it is planned to include 70 women in total in 2 groups (study and control), with 35 women in each group. all individuals who want to respond to the survey are included in the sample. the process of finding a subject continues until the desired size is reached. in addition, during the data collection process, participants were asked; they are asked whether they are diagnosed with pcos and those who answer "yes" are included in the sample. within the scope of the research, the voluntariness of the participants is essential and both written and verbal consents are obtained from each participant through an informed consent form. "personal information form" and "polycystic ovary syndrome quality of life-50 scale" created by the researchers were used as data collection tools.


Eligibility criteria:
inclusion criteria: individuals who are over 18 years of age, open to communication, diagnosed with pcos, have no mental problems that require treatment, have no physical, mental or five sense disabilities, speak turkish and can read and write, and volunteer to participate in the study. exclusion criteria: individuals who are under 18 years old, not open to communication, diagnosed with pcos, require treatment for significant mental health issues, have physical, mental, or sensory impairments, cannot speak or read and write turkish, and are not willing to participate in the study.

Keywords: polycystic ovary syndrome quality of life education
kinesiotaping effect glenohumeral shoulder subluxation

Conditions: Stroke; Subluxation, Glenohumeral

Summary: to evaluate the effectiveness of the kinesiotaping on pain, recovery of movement and daily life activities in turkish hemiplegic patients.


Eligibility criteria:
inclusion criteria: * (1) 18 to 90 years of age, (2) stroke onset within one year, (3) shoulder subluxation in the involved upper extremity and (4) being oriented and cooperative. exclusion criteria: * (1) global aphasia, (2) malignancy, (3) previous shoulder pain or surgery, (4) other neuromuscular disorders and (5) severe cardiopulmonary disease that affects daily life activities.
fsme immun new follow-up to study 199 in children aged 1 to 6 years

Conditions: Encephalitis, Tick-borne

Summary: the purpose of this study is to investigate the safety and immunogenicity of the third vaccination with one of three different concentrations of a tbe vaccine in all subjects who completed two vaccinations in one of the three treatment groups of baxter study 199 (a dose-finding study to investigate the safety and immunogenicity of two vaccinations with fsme immun new in healthy subjects aged 1 to 6 years).


Eligibility criteria:
inclusion criteria: all volunteers who participated in baxter study 199 and received two vaccinations will be invited to participate. male and female children will be eligible for participation in this study if: * they received two vaccinations with one of the three different dosages of fsme immun new during the course of baxter study 199 * written informed consent from the legal guardian is available. exclusion criteria: there are no specific exclusion criteria for this study entry. however volunteers will be assessed for eligibility to receive a third vaccination. volunteers will be excluded from vaccination and consecutive visits in this study if they: * are not clinically healthy, (i. e. the physician would have reservations vaccinating with fsme immun new outside the scope of a clinical trial) * have already been administered a third tbe vaccination elsewhere after the two vaccinations in baxter study 199 * have had an allergic reaction to one of the components of the vaccine since the last vaccination in baxter study 199 * suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids, chemotherapeutics) that can be expected to influence immunological functions * have received banked human blood or immunoglobulins within one month of study entry * are known to be hiv positive (a special hiv test is not required for the purpose of the study) since the last visit of baxter study 199 * have had a vaccination against yellow fever and / or japanese b-encephalitis since the last visit in baxter study 199 * had received an investigational new drug within 6 weeks prior to study start
rehabilitation program for cognitive deficits in ugandan children after cerebral malaria

Conditions: Malaria, Cerebral

Summary: the purpose of this study is to determine whether computerised cognitive rehabilitation training improves cognition in children who have had cerebral malaria.

cerebral malaria affects several children in sub-saharan africa leaving some survivors with cognitive problems especially in attention and memory. there are currently no tested interventions for such deficits resulting from infectious diseases like malaria or other causes. providing such interventions will go a long way in helping these children achieve their full potential.

Eligibility criteria:
cm group inclusion criteria: * aged five to 15 years, presenting with asexual forms of p. falciparum malaria on a peripheral blood smear, unarousable coma (not able to localize a painful stimulus) and no other cause for coma (normal csf). cm group exclusion criteria: * history of or present meningitis, encephalitis, prior cm, sickle cell disease (scd), hiv infection, epilepsy, multiple seizures, developmental delay and history of hospitalization for malnutrition. healthy control group inclusion criteria: * aged five to 15 years with no other illness at present, within two years of the cm child (for cm children aged 5 and 6 years, the hc's age wont go below 5 and for cm children aged 14 and 15, the hc's age wont go above 15 years). healthy control group exclusion criteria: * history of or present bacterial meningitis, encephalitis, cm, scd, hiv infection, history of hospitalization for malnutrition and any chronic illness for which the patient is currently taking medication.

Keywords: malaria, cerebral
study of a booster dose of hib-menc conjugate vaccine vs infanrix hexa when given to 14 month old subjects

Conditions: Neisseria Meningitidis; Haemophilus Influenzae Type b

Summary: the purpose of this study is to evaluate the immunogenicity, safety and reactogenicity of a booster dose of the hib-menc conjugate vaccine when given to healthy subjects aged 13 to 14 months who were primed with three doses of hib-menc compared to a booster dose of infanrix hexa given to subjects primed with three doses of infanrix hexa and meningitec.

the study is open and infanrix hexa will serve as active control. subjects will receive one vaccine dose of either hib-menc or infanrix hexa, and will have 2 blood samples taken: before and one month after vaccination. subjects who will receive a booster dose of hib-menc were primed with 3 doses of infanrix penta + hib-menc or 2 doses of neisvac-c and infanrix hexa / infanrix ipv/hib.

Eligibility criteria:
inclusion criteria: * healthy male or female between, and including, 13 and 14 months of age * having participated in the primary vaccination study 217744/097. exclusion criteria: * previous vaccination against or history of or known exposure to diphtheria, tetanus, pertussis, hepatitis b, polio, h. influenzae type b (hib) and/or meningococcal serogroup c disease except if within the framework of study 217744/097 * any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (hiv) infection * a family history of congenital or hereditary immunodeficiency * history of any neurologic disorders or seizures
simeprevir in combination with sofosbuvir in treatment-naïve or -experienced adults with chronic genotype 4 hepatitis c virus infection

Conditions: Chronic Hepatitis C

Summary: this study will look at the safety and efficacy of 8 week and 12 week treatment with sofosbuvir and simeprevir in treatment-naïve and treatment-experienced patients with chronic hepatitis c genotype 4.

patients with confirmed absence of cirrhosis will receive 8 weeks of treatment with sofosbuvir and simeprevir. patients with confirmed presence of cirrhosis will receive 12 weeks of treatment with sofosbuvir and simeprevir. all patients will followed for 24 weeks post-treatment. presence or absence of cirrhosis will be evaluated by fibroscan if no historical liver biopsy or fibroscan is available.

Eligibility criteria:
inclusion criteria: * hcv genotype 4 infection * hcv rna \>10,000 iu/ml at screening. exclusion criteria: * evidence of clinical hepatic decompensation (history or current evidence of ascites, bleeding varices or hepatic encephalopathy). * any liver disease of non-hcv etiology. this includes, but is not limited to, acute hepatitis a, drug- or alcohol-related liver disease, autoimmune hepatitis, hemochromatosis, wilson's disease, alpha-1 antitrypsin deficiency, non-alcoholic steatohepatitis, primary biliary cirrhosis, or any other non-hcv liver disease considered clinically significant by the investigator. * infection/co-infection with hcv non-genotype 4. * co-infection with human immunodeficiency virus (hiv) type 1 or type 2 (hiv-1 or hiv-2) (positive hiv-1 or hiv-2 antibodies test at screening). * co-infection with hepatitis-b virus (hepatitis-b-surface-antigen \[hbsag\] positive). * presence of significant co-morbidities or conditions that would compromise the subject's safety and could interfere with the subject's participation for the full duration of the study in the opinion of the investigator * previously been treated with any direct acting anti-hcv agent (approved or investigational) for chronic hcv infection.
transforming health and reducing perinatal anxiety through virtual engagement

Conditions: Anxiety

Summary: the goal of this clinical trial is to evaluate whether digital cognitive behavioral therapy (dcbt) can be used to address clinical anxiety in marginalized and low-income pregnant people in california. the main question it aims to answer is: what is the efficacy of digital cognitive behavioral therapy (dcbti) for reducing clinical anxiety among marginalized and low-income pregnant people? participants will receive digital cognitive behavioral therapy immediately, or 10 weeks after enrollment (i.e., waitlist control). participants will complete surveys and interviews until 6-8 weeks postpartum.

although therapist-delivered cognitive behavioral therapy (cbt) has been shown to be effective for treating clinical anxiety in non-marginalized pregnant populations, barriers to access exist among pregnant people (e.g., long waitlists, childcare issues, limited appointment windows). recent innovations have focused on addressing barriers to cbt by adapting it for automated, digital delivery. digital cbt (dcbt) has been shown to be effective for treating clinical anxiety in mostly white, higher socioeconomic status, pregnant, and non-pregnant populations. person-centered adaptations of dcbt are likely needed to maximize access in marginalized and low-income pregnant people. this study addresses the critical need to evaluate whether dcbt can be used to address clinical anxiety in marginalized and low-income pregnant people in california.

Eligibility criteria:
inclusion criteria: * california medical participant * pregnant, 8-27 weeks gestation by ultrasound * 18-years of age or older * english speaking * 9th grade level of education or more * daily access to web-enabled computer, smart phone, or tablet * current elevated anxiety symptoms (score on the seven item generalized anxiety disorder (gad-7)questionnaire of 10 or more exclusion criteria: * received cbt for anxiety in the last 12-months * new or changed dose of prescription medication for anxiety, depressive symptoms, or poor sleep in \< 4weeks * self-reported diagnosis of schizophrenia, psychosis, bipolar disorder, seizure disorder, substance use disorder, severe cognitive impairment (characterized by experiences like forgetting events, having decreased periods of alertness, decreased social awareness) * recent trauma to the head or brain damage * serious physical health concerns necessitating surgery or hospitalization in the last 6-months
randomized study of hla-mismatched dsi to treat relapse leukemia after hla- matched transplantation

Conditions: Relapse Leukemia

Summary: the relapse leukemia patients after transplantation were divided into two groups randomly. group d1: patients received first-donor stem cells infusion(dsi) treatment with or without chemotherapy; group d2: patients received second-donor dsi treatment with or without chemotherapy. the second donors were preferably donors who were genetically related and had more hla-match locus. the re-induction chemotherapy regimen was primarily mat(mitoxantrone, cytarabine, teniposide ) for acute myeloid leukemia (aml) and vmcld(vincristine, teniposide, cyclophosphamide, l-asparaginase, dexamethasone) for acute lymphocytic leukemia (all), and no graft versus host disease(gvhd) prevention was conducted pre- and post- therapy.

evaluation indications include bone marrow morphology,hematopoietic recovery (neutrophil and platelet), 100-day transplantation-related mortality (trm), donor chimerism, acute gvhd, chronic gvhd, disease free survival (dfs), and overall survival (os). the cut-time of the follow-up was oct, 2013. dfs was defined as the time between the date of transplantation to the death or relapse. os was defined as the time from diagnosis to death or to the last date of follow-up until oct. 2013.

Eligibility criteria:
inclusion criteria: * eligible patients were between 9 and 67 years of age with de novo diagnosed or treated-related acute leukemia relapsed after hla-matched hematological stem cell transplantation from feb 2005 to feb 2013 * relapse was morphologically and molecularly diagnosed,with the help of cytogenetic and engraftment. * eastern cooperative oncology group (ecog) performance status was 0 to 2 exclusion criteria: * patients without receiving cr will not receive further post-remission trial therapy * the patients of aml-m3 were excluded from this study.

Keywords: relapse leukemia dsi
a study of ruxolitinib phosphate cream when applied to patients with plaque psoriasis

Conditions: Psoriasis

Summary: the study is comprised of two parts. the first portion of this study will be a double-blind, sponsor-unblinded, vehicle-controlled study with application of ruxolitinib or vehicle to paired lesions at least 15 cm apart in patients with active but stable plaque psoriasis. part 2 of the study is a double-blind, sponsor unblinded, comparison of ruxolitinib with two fda approved products in patients with active but stable plaque psoriasis.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) of 17 to 40 kg/m2 * subjects must have two comparable psoriatic lesions measuring between 9 and 100 cm2 and these target lesions must be similar in size to each other, and separated by at least 15 cm. exclusion criteria: * subjects with lesions solely involving the palms of the hands or soles of the feet or intertriginous areas, the scalp or the face. * subjects with pustular psoriasis or erythroderma. * subjects currently on other topical agents or uvb therapy within 2 weeks of the first dose of study medication. * subjects receiving puva within 4 weeks of the first dose of study medication. * subjects receiving systemic retinoids, etanercept, adalimumab or efalizumab or oral immunosuppressives within 3 months prior to the first dose of study medication. * subjects receiving any other biological therapy (infliximab, alefacept, abatacept, etc) within 3 months of the first dose of study medication.
intervention program for patients with mild cognitive impairment

Conditions: Mild Cognitive Impairment

Summary: mild cognitive impairment (mci) is a syndrome defined as a cognitive decline that is more severe than can be explained by an individual's age and education. one study in the united states found that mci caregivers have experienced distress in association with caregiver burden. the prevalence of mci for people age 65 and older ranges from 3% to 19%. understanding the process of family caregiving provides a knowledge base for the health professionals when developing effective interventions. however, little is known about the phenomenon of family caregiving to patients with mci in taiwan. therefore, the purpose of the proposed study is to develop a theoretical model and a model-based intervention program for family caregivers of patients with mci in taiwan, and pilot test it in a clinical trial.

mild cognitive impairment (mci) is a syndrome defined as a cognitive decline that is more severe than can be explained by an individual's age and education. one study in the united states found that mci caregivers have experienced distress in association with caregiver burden. the prevalence of mci for people age 65 and older ranges from 3% to 19%. understanding the process of family caregiving provides a knowledge base for the health professionals when developing effective interventions. however, little is known about the phenomenon of family caregiving to patients with mci in taiwan. therefore, the purpose of the proposed study is to develop a theoretical model and a model-based intervention program for family caregivers of patients with mci in taiwan, and pilot test it in a clinical trial. to conduct a small scale pilot randomized control trial (total n = 60; 30 in each group) to pilot test the intervention program. the intervention group will receive the caregiver training program, and the control group received printed sheets with general information on mci and dementia such as the causes, courses and symptoms. at 1 month, 3 months, and 6 months after the intervention group will complete the two-session training program, both groups will receive a follow-up assessment for preparedness, hrqol and depressive symptoms. to minimize attrition, caregivers in both groups will receive monthly follow-up phone calls from the first to the sixth month. changes in outcome variables will be analyzed using hierarchical linear models, in order to provide a reference for further formal clinical trial.

Eligibility criteria:
patients' inclusion criteria: * age 65 years or older * being diagnosed as having mci by a neurologist or a psychiatris * being cared for in a home setting patients' exclusion criteria: * terminally ill caregivers' inclusion criteria: * age 20 years or older * assuming primary responsibility for the care of the frail elderly person caregivers' exclusion criteria: * terminally ill

Keywords: mild cognitive impairment family caregiver intervention program elders